# Druggability Assessment of Age-Related Neurodegeneration Hypotheses
## 1. Senescence-Activated NAD+ Depletion Rescue
**Revised Confidence: 0.45**
### Druggability: HIGH
**CD38 Inhibitors:**
- **78c**: Potent, selective CD38 inhibitor (IC50 = 40 nM), brain-penetrant
- **Kuromanin**: Natural flavonoid CD38 inhibitor, oral bioavailability
- **Apigenin**: Dual CD38/CD157 inhibitor, clinical safety data available
**NAD+ Precursors:**
- **Nicotinamide riboside (NR)**: ChromaDex's NIAGEN®, FDA GRAS status
- **Nicotinamide mononucleotide (NMN)**: Multiple suppliers, ongoing trials
- **NAD+**: Direct IV administration (NAD+ injectable solutions)
### Existing Clinical Programs:
- **NCT04482452**: NR in Alzheimer's disease (Washington University)
- **NCT03816020**: NMN in healthy aging (University of Washington)
- ChromaDex (NASDAQ: CDXC) - TRU NIAGEN® commercialized
### Competitive Landscape:
- **Elysium Health**: BASIS (NR + pterostilbene) - $50M+ raised
- **Alive by Science**: NMN products, direct-to-consumer
- **Metro International Biotech**: NAD+ IV clinics expanding
### Safety Concerns:
- CD38 inhibition may impair immune function (CD38 on NK cells, T cells)
- High-dose NAD+ precursors linked to liver toxicity in some reports
- Potential interference with normal circadian NAD+ cycling
### Timeline & Cost:
- **Repurposing existing CD38 inhibitors**: 2-3 years, $20-50M
- **Novel brain-penetrant CD38 inhibitor**: 5-7 years, $100-200M
- **NAD+ precursor trials**: 1-2 years, $5-15M
---
## 2. SASP-Mediated Complement Cascade Amplification
**Revised Confidence: 0.65**
### Druggability: MODERATE
**C1q Inhibitors:**
- **ANX005** (Annexon): Humanized anti-C1q mAb, brain-penetrant
- **ANX007**: Next-gen C1q inhibitor with enhanced CNS penetration
- **Mini-complement inhibitors**: Small molecule C1q antagonists in development
**C3 Inhibitors:**
- **Pegcetacoplan** (Apellis): Approved C3 inhibitor for PNH/GA
- **APL-2**: Subcutaneous C3 inhibitor
- **Compstatin analogs**: Multiple companies developing variants
### Existing Clinical Programs:
- **NCT04701164**: ANX005 in Huntington's disease (Annexon/Roche)
- **NCT03701230**: ANX005 in ALS (Annexon)
- **NCT04146967**: Pegcetacoplan in geographic atrophy (Apellis)
### Competitive Landscape:
- **Annexon Biosciences** (NASDAQ: ANNX): $200M+ funding, Roche partnership
- **Apellis Pharmaceuticals** (NASDAQ: APLS): $2B+ market cap, commercial drug
- **Ra Pharmaceuticals** (acquired by UCB for $2.1B): C5 inhibitor zilucoplan
### Safety Concerns:
- Increased infection risk (complement deficiency syndromes)
- Potential autoimmune complications
- Need for infection monitoring protocols
### Timeline & Cost:
- **ANX005 CNS trials**: 3-4 years, $100-300M (partnership model)
- **Novel brain-penetrant C3 inhibitor**: 6-8 years, $200-400M
- **Biomarker development essential**: $10-20M additional
---
## 5. SASP-Driven Aquaporin-4 Dysregulation
**Revised Confidence: 0.55**
### Druggability: LOW-MODERATE
**AQP4 Enhancers:**
- **TGN-020**: AQP4 inhibitor (reverse pharmacology approach limited)
- **Acetazolamide**: Carbonic anhydrase inhibitor, affects AQP4 indirectly
- **Gene therapy approaches**: AAV-AQP4 under development
**Anti-inflammatory approaches:**
- **TNF-α inhibitors**: Adalimumab, infliximab (limited CNS penetration)
- **IL-1β inhibitors**: Anakinra, canakinumab (poor BBB penetration)
- **Brain-penetrant variants**: XPro1595 (selective TNF-α inhibitor)
### Existing Clinical Programs:
- **NCT02265562**: XPro1595 in Alzheimer's disease (INmune Bio)
- **NCT03943264**: Sargramostim (GM-CSF) in Alzheimer's (Partner Therapeutics)
- Limited AQP4-specific programs currently
### Competitive Landscape:
- **INmune Bio** (NASDAQ: INMB): XPro1595, $50M+ raised
- **Denali Therapeutics** (NASDAQ: DNLI): BBB-crossing biologics platform
- **Academic programs**: Multiple universities working on glymphatic enhancement
### Safety Concerns:
- AQP4 manipulation could cause cerebral edema
- Anti-TNF therapies increase infection risk, potential malignancy
- Disruption of normal glymphatic rhythms
### Timeline & Cost:
- **XPro1595 expansion trials**: 2-3 years, $30-80M
- **Novel AQP4 enhancers**: 6-8 years, $150-300M
- **Gene therapy approach**: 7-10 years, $200-500M
---
## 7. SASP-Mediated Cholinergic Synapse Disruption
**Revised Confidence: 0.45**
### Druggability: MODERATE
**MMP Inhibitors:**
- **Marimastat**: Pan-MMP inhibitor, failed in cancer but CNS applications unexplored
- **Batimastat**: MMP-2/9 selective, limited by BBB penetration
- **GM6001**: Broad-spectrum MMP inhibitor, research tool
- **SB-3CT**: Selective gelatinase inhibitor, some CNS penetration
**Perineuronal Net Restoration:**
- **Chondroitin sulfate proteoglycans**: Injectable CSPGs under development
- **Hyaluronidase inhibitors**: Indirect PNN protection
- **Matrix modifying enzymes**: ChABC alternatives
### Existing Clinical Programs:
- **NCT03284489**: Doxycycline (MMP inhibitor) in traumatic brain injury
- Limited PNN-specific therapeutic programs
- Multiple academic initiatives on extracellular matrix repair
### Competitive Landscape:
- **No major pharma focus** on MMP inhibition for CNS (post-cancer failures)
- **Catalyst Biosciences**: MMP inhibitors for other indications
- **Academic programs**: Strong interest in PNN biology, limited translation
### Safety Concerns:
- MMP inhibition caused musculoskeletal syndrome in cancer trials
- Disruption of normal tissue remodeling and wound healing
- Potential interference with synaptic plasticity
### Timeline & Cost:
- **Repurposed MMP inhibitor trials**: 2-3 years, $15-40M
- **CNS-optimized MMP inhibitors**: 5-7 years, $100-250M
- **PNN restoration approach**: 6-8 years, $150-300M
---
## OVERALL INVESTMENT RECOMMENDATION
### Tier 1 (Highest Priority):
1. **Complement inhibition (Hypothesis 2)**: Established drugs, active clinical programs, clear path forward
2. **NAD+ pathway (Hypothesis 1)**: Multiple approved precursors, strong academic interest, manageable risk
### Tier 2 (Conditional Investment):
3. **AQP4 modulation (Hypothesis 5)**: Novel target, requires biomarker development, moderate risk
4. **MMP inhibition (Hypothesis 7)**: Historical safety concerns, limited competitive interest
### Key Success Factors:
- **Biomarker development**: All approaches need robust target engagement and efficacy markers
- **Patient stratification**: Senescent cell burden quantification essential
- **Combination approaches**: Likely synergistic with senolytic therapies
- **Regulatory strategy**: FDA breakthrough therapy designation for compelling preliminary data
### Recommended Budget Allocation:
- **Complement program**: $50-100M over 3-4 years
- **NAD+ precursor trials**: $10-30M over 2-3 years
- **Biomarker development**: $15-25M across all programs
- **Platform technologies**: $20-40M for delivery systems
**Total estimated investment**: $95-195M for comprehensive portfolio approach.